Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors

Journal of Clinical Gastroenterology

Volumn 43, Issue 3, 2009, Pages 280-286

  Di Benedetto, Fabrizio ^a   Di Sandro, Stefano ^a   De Ruvo, Nicola ^a   Spaggiari, Mario ^a   Montalti, Roberto ^a   Ballarin, Roberto ^a   Cappelli, Gianni ^a   Gerunda, Giorgio E ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Liver transplantation; Nephrotoxicity; Sirolimus monotherapy

Indexed keywords

CALCINEURIN INHIBITOR; ERYTHROPOIETIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; PEGINTERFERON; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTOXICITY; PANCYTOPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; UREA BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; CALCINEURIN; COHORT STUDIES; CREATININE; CYCLOSPORINE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 67650904764     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181739ff8     Document Type: Article

References (24)

1. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present and future. Semin Nephrol. 2000; 20:108-125. Review.
2. Handschumacher RE, Harding MW, Rice J, et al. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984;226:544-547. (Pubitemid 14018525)
3. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807-815. (Pubitemid 121001714)
4. Monsour HP Jr, Wood RP, Dyer CH, et al. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis. 1995;15:123-132. Review.
5. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transpl Int. 1994;7(suppl 1):S52-S57.
6. Wiesner R, Klintmalm G, McDiarmid S. Rapamune Liver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. Am J Transplant. 2002;2:464.
7. Gonwa TA, MaiML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72:1934-1939.
8. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl. 2001;7(11 suppl 1): S22-S26. Review.
9. Flanagan WM, Crabtree GR. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition. Ann N Y Acad Sci. 1993;696:31-37.
10. Thomson AW, Woo J. Immunosuppressive properties of FK- 506 and rapamycin. Lancet. 1989;2:443-444.
11. Dumont FJ, Melino MR, Staruch MJ, et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol. 1990;144: 1418-1424.
12. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007;46:840-848. (Pubitemid 46529039)
13. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990; 144:251-258.
14. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74:1070-1076. (Pubitemid 35216097)
15. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3 suppl): 7S-14S. Review.
16. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl. 2003;9:741-747. (Pubitemid 36874464)
17. Seaberg EC, Belle SH, Beringer KC, et al. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl. 1998;12:17-37.
18. Böker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology. 1997;25:203-210. (Pubitemid 27015011)
19. O'Grady JG, Burroughs A, Hardy P, et al. UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360:1119-1125.
20. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8(10 suppl 1):S14-S18.
21. Fisher L, Henley K, Lucey M. Acute cellular rejection after liver transplantation: variability, morbidity, and mortality. Liver Transpl Surg. 1995;1:10-15.
22. Fairbanks KD, Eustace JA, Fine D, et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl. 2003;9: 1079-1085. (Pubitemid 37304464)
23. Lam P, Yoshida A, Brown K, et al. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci. 2004;49:1029-1035. (Pubitemid 39012290)
24. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl. 2003;9:126-129. (Pubitemid 36204562)